CoChat

Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF -mutant lung cancer

Open access
Okimoto, Ross A., Lin, Luping, Olivas, Victor, Chan, Elton, Markegard, Evan, Rymar, Andrey, Neel, Dana, Chen, Xiao, Hemmati, Golzar, Bollag, Gideon, Bivona, Trever G. · 2016 · Proceedings of the National Academy of Sciences
Cited by 78

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Significance: Oncogenic mutations in the BRAF protein kinase occur in a large number of patients with lung cancer, the number one cause of cancer mortality worldwide. Despite the relatively high frequency (2–7%) of various oncogenic BRAF alleles in human lung adenocarcinoma (LA), the biological and clinical relevance of these mutations and the optimal therapeutic strategy to improve outcomes remains poorly defined. We report the preclinical efficacy of a next-generation BRAF kinase inhibitor across a spectrum of clinically relevant BRAF -mutant nonsmall cell lung cancer (NSCLC) models. Our results provide biological insight into the regulation of BRAF oncogene dependence and identify strategies to improve outcomes in patients with BRAF -mutant lung cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1610456113

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 78

Metadata

Authors
Okimoto, R. A., Lin, L., Olivas, V., Chan, E., Markegard, E., Rymar, A., Neel, D., Chen, X., Hemmati, G., Bollag, G., & Bivona, T. G.
Venue
Proceedings of the National Academy of Sciences
Published
2016-11-09
Volume
113
Issue
47
Pages
13456-13461
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2551781955
Cited by
78
References
10
FWCI
8.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF -mutant lung cancer. https://app.cochat.ai/papers/10.1073/pnas.1610456113
The paper
Okimoto, R. A., Lin, L., Olivas, V., Chan, E., Markegard, E., Rymar, A., Neel, D., Chen, X., Hemmati, G., Bollag, G., & Bivona, T. G. (2016). Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF -mutant lung cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1610456113

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.